Bookmarks
The effectiveness of opicapone treatment compared to entacapone in Parkinson's disease using electronic primary healthcare records and linked secondary care data
Safe People
Pharmatelligence Ltd
Commercial
Craig Currie - Chief Investigator - Pharmatelligence LimitedEllen Berni - Corresponding Applicant - Pharmatelligence LimitedDavid Heaton - Collaborator - OPEN VIE ( Harvey Walsh Ltd )Francesca Morgante - Collaborator - St George'sUniversity of LondonK Ray Chaudhuri - Collaborator - King's College LondonMatthew O'Connell - Collaborator - OPEN VIE ( Harvey Walsh Ltd )Myriam Alexander - Collaborator - OPEN VIE ( Harvey Walsh Ltd )Rhiannon Thomason - Collaborator - OPEN VIE ( Harvey Walsh Ltd )Stoyan Minchev - Collaborator - Bial Phama UK LtdValentina Di Foggia - Collaborator - Bial Phama UK Ltd
Safe Projects
CPRD462
Opicapone is a treatment for Parkinson’s disease patients which is added to other therapies when symptoms are not controlled (known as end of dose on-off phenomena). Although Parkinson’s disease is diagnosed by its motor symptoms, non-motor symptoms such as sleep disturbances are also prevalent and can be more disabling than the motor symptoms.
Parkinson’s disease is associated with disabling motor and non-motor symptoms (including sleep disturbances). Opicapone is a catechol-O-methyltransferase (COMT) inhibitor indicated in Parkinson’s disease as an adjunct to levodopa and dopa-decarboxylase inhibitors in patients with end-of-dose motor fluctuations. This study aims to evaluate the effectiveness of opicapone in Parkinson’s disease in routine practice.
24/03/2021
Safe Data
HES Accident and Emergency
HES Admitted Patient Care
HES Outpatient
Safe Setting
Release